Dr. Mark D. Akin, MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 172
Licensed in Texas since 1979, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
TX license F3699 (first issued 1979; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- North Austin Medical Center Austin, TX
Medical groups
- Aa Obgyn PLLC (38 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 172
- Services billed
- 597
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 124 | 93 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 71 | 71 |
| Dxa bone density measurement of hip, pelvis, spine | 47 | 47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 45 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Progesterone (progesterone, micronized) Other prescribers in Austin, TX | 117 |
| Levothyroxine Sodium Other prescribers in Austin, TX | 92 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Austin, TX | 34 |
| Estradiol Other prescribers in Austin, TX | 27 |
| Ozempic (semaglutide) Other prescribers in Austin, TX | 25 |
| Myrbetriq (mirabegron) Other prescribers in Austin, TX | 18 |
| Atorvastatin Calcium Other prescribers in Austin, TX | 17 |
| Estradiol (Twice Weekly) (estradiol) Other prescribers in Austin, TX | 15 |
| Triamterene-Hydrochlorothiazid (triamterene/hydrochlorothiazid) Other prescribers in Austin, TX | 13 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Austin, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 38 payments worth $1,065 in total to this clinician.
| Novo Nordisk Inc | $382 |
|---|---|
| Sumitomo Pharma America, Inc. | $180 |
| Biogen, Inc. | $132 |
| Hologic Sales and Service, LLC | $86.83 |
| Mayne Pharma Commercial LLC | $68.47 |
| Ethicon US, LLC | $49.35 |
| Coloplast Corp | $37.73 |
| Boston Scientific Corporation | $36.47 |
| Food and Beverage | $1,065 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,464 in research payments for these studies, mostly to the institutions running them.
- A phase iii, randomized, multicenter, parallel-group, double-blind, do
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.